Clinical Trial Update: A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels [Phase 2]

View source ↗

Summary

Alnylam's Phase 2 trial evaluating Lumasiran in adults with recurrent calcium oxalate kidney stones and elevated urinary oxalate levels has been terminated, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Calcium Oxalate Nephrolithiasis

Drugs mentioned

• Lumasiran (lumasiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Recurrent Calcium Oxalate Kidney Stone Disease, Elevated Urinary Oxalate Levels | Phase 2 | Status: TERMINATED | Results posted: 2024-05-22